JP2019218284A - Oral composition for improving juvenile learning ability, and method for improving juvenile learning ability - Google Patents
Oral composition for improving juvenile learning ability, and method for improving juvenile learning ability Download PDFInfo
- Publication number
- JP2019218284A JP2019218284A JP2018115554A JP2018115554A JP2019218284A JP 2019218284 A JP2019218284 A JP 2019218284A JP 2018115554 A JP2018115554 A JP 2018115554A JP 2018115554 A JP2018115554 A JP 2018115554A JP 2019218284 A JP2019218284 A JP 2019218284A
- Authority
- JP
- Japan
- Prior art keywords
- ingestion
- oral composition
- test
- learning ability
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、若齢者の脳機能を改善させる作用を有し、学習能力向上に寄与する組成物に関する。 The present invention relates to a composition having an effect of improving brain function of a young person and contributing to improvement of learning ability.
高齢者社会に伴い、認知症患者が急増しており、脳機能改善作用を有する物質の探索が盛んに行われている。
高麗人参(朝鮮人参)抽出物においても、脳機能改善作用について報告されている。例えば、特許文献1には朝鮮人参の実抽出物を有効成分として含む脳活性化用組成物が開示されている。また、特許文献2にはニンジン抽出物、イチョウ葉抽出物、サフラン柱頭の抽出物、ダイズ抽出物を配合した虚血性の脳血管疾患および老年痴呆を処置するための漢方薬組成物が開示されている。また、特許文献3には人参由来の糖リポタンパク質ジントニンを有効成分として含む学習能力向上および記憶増進用薬学組成物が開示されている。また、特許文献4には人参由来のジンセノサイドRg3薬用組成物水溶液を記憶改善に使用する薬剤に使用することが開示されている。
With the aging society, the number of dementia patients is rapidly increasing, and a search for substances having a brain function improving effect is being actively conducted.
Ginseng (Korean ginseng) extract has also been reported to improve brain function. For example, Patent Document 1 discloses a brain-activating composition containing a ginseng berry extract as an active ingredient. Patent Document 2 discloses a Chinese herbal composition for treating ischemic cerebrovascular disease and senile dementia, which contains a carrot extract, a ginkgo biloba extract, a saffron stigma extract, and a soybean extract. . Patent Literature 3 discloses a pharmaceutical composition for improving learning ability and improving memory, which contains ginseng-derived sugar lipoprotein gintonin as an active ingredient. Patent Literature 4 discloses that ginseng-derived ginsenoside Rg3 medicinal composition aqueous solution is used as a drug used for improving memory.
一方、近年、高齢者ではなく、10代の若齢者においても、脳機能を改善し、学習能力や記憶力を増強することが望まれている。
しかしながら、従来の脳機能改善作用を有するとされている物質は、高齢者の認知症の予防、改善を対象としているものが多く、認知症等を改善する効果があったとしても、脳の発育期である若齢者に対しても脳機能改善作用を示すか否かについての詳細は不明であるのが実情である。特許文献1〜4で開示された高麗人参抽出物においても、若齢者に対して脳機能改善作用を示すか否かについて評価されてはいない。
On the other hand, in recent years, it has been desired that not only elderly people but also teenagers improve their brain functions and enhance their learning ability and memory ability.
However, many substances that have been reported to have an effect of improving brain function are intended to prevent or improve dementia in the elderly, and even if they have the effect of improving dementia, etc. In fact, it is unclear whether or not a young person, who is in a childhood stage, has a cerebral function improving effect. The ginseng extracts disclosed in Patent Literatures 1 to 4 have not been evaluated as to whether or not they show a cerebral function improving effect on young people.
かかる状況下、本発明の目的は、若齢者の学習能力向上効果を有する経口組成物を提供することである。 Under such circumstances, an object of the present invention is to provide an oral composition having an effect of improving the learning ability of young people.
本発明者は、上記課題を解決すべく鋭意研究を重ねた結果、下記の発明が上記目的に合致することを見出し、本発明に至った The present inventors have conducted intensive studies to solve the above-described problems, and as a result, have found that the following inventions meet the above objects, and have reached the present invention.
すなわち、本発明は、以下の発明に係るものである。
<1> 高麗人参(Panax ginseng)の根茎、葉部及び茎部の1種以上から選択される部位の加工物を有効成分として含有する若齢者学習能力向上のための経口組成物。
<2> 前記加工物が、蒸煮した根茎の乾燥物の粉砕物又は抽出物である<1>に記載の経口組成物。
<3> 形態が、錠剤状、粉末状、液状、顆粒状又はカプセル状である<1>又は<2>に記載の経口組成物。
<4> 蒸煮した根茎の乾燥物の抽出物及びブドウ糖を含有し、顆粒状である<3>に記載の経口組成物。
<5> <1>から<4>のいずれかに記載の経口組成物を含有する機能性食品。
That is, the present invention relates to the following inventions.
<1> An oral composition for improving the learning ability of young people, comprising as an active ingredient a processed product of a site selected from one or more of rhizomes, leaves and stems of ginseng (Panax ginseng).
<2> The oral composition according to <1>, wherein the processed product is a pulverized product or an extract of a dried steamed rhizome.
<3> The oral composition according to <1> or <2>, wherein the form is a tablet, powder, liquid, granule, or capsule.
<4> The oral composition according to <3>, which contains an extract of a dried steamed rhizome and glucose, and is granular.
<5> A functional food containing the oral composition according to any one of <1> to <4>.
<1A> <1>から<4>のいずれかに記載の経口組成物を、若齢者に経口投与して学習能力を向上させる方法(但し、ヒトに対する医療行為を除く。)。
<2A> 対象となる若齢者が、10歳以上20歳以下である<1A>に記載の方法。
<1A> A method of improving the learning ability by orally administering the oral composition according to any one of <1> to <4> to a young person (however, excluding medical practice for humans).
<2A> The method according to <1A>, wherein the target young person is 10 to 20 years old.
本発明によれば、若齢者に対する学習能力向上効果が認められる経口組成物が提供される。 ADVANTAGE OF THE INVENTION According to this invention, the oral composition in which the learning ability improvement effect with respect to a young person is recognized is provided.
以下、本発明について例示物等を示して詳細に説明するが、本発明は以下の例示物等に限定されるものではなく、本発明の要旨を逸脱しない範囲において任意に変更して実施できる。 Hereinafter, the present invention will be described in detail with reference to examples and the like, but the present invention is not limited to the following examples and the like, and can be arbitrarily modified and implemented without departing from the gist of the present invention.
本発明は、高麗人参(Panax ginseng)の根茎、葉部及び茎部の1種以上から選択される部位の加工物を有効成分として含有とする若齢者学習能力向上のための経口組成物(以下、「本発明の経口組成物」と記載する。)に関する。 The present invention relates to an oral composition for improving the learning ability of young people, comprising a processed product of a site selected from one or more of rhizomes, leaves and stems of ginseng (Panax ginseng) as an active ingredient. Hereinafter, it is referred to as “the oral composition of the present invention”.).
本発明の経口組成物の原料は、ウコギ科の多年宿根草である高麗人参(Panax ginseng)の根茎、葉部又は茎部である。高麗人参は天然物であってもよく、人工的に栽培してものであってもよい。通常廃棄する高麗人参の葉部や茎部も有効利用することができるが、根茎(特には6年根)が好ましく使用される。 The raw material of the oral composition of the present invention is a rhizome, a leaf or a stem of Panax ginseng, which is a perennial rhizome of the araliaceae family. Ginseng may be a natural product or artificially cultivated. The leaves and stems of ginseng, which are usually discarded, can also be effectively used, but rhizomes (particularly, six-year roots) are preferably used.
高麗人参の使用部位(根茎、葉部又は茎部)は、前処理せずにそのまま使用することができるうえ、細断等の前処理を行って使用することもできる。 The site of use of ginseng (rhizome, leaf or stem) can be used as it is without pretreatment, and can also be used after pretreatment such as shredding.
本発明において「加工物」は、高麗人参の使用部位(根茎、葉部又は茎部)に対し任意の加工処理を行ったものを意味する。
任意の加工処理としては、本発明の効果を損なわないものであるならば、適宜のものが選択でき、例えば、蒸煮処理、乾燥処理、加熱処理、抽出処理などが挙げられる。これらの処理は適宜組み合わせて行うことができる。
In the present invention, the "processed product" means a product obtained by subjecting a used portion (rhizome, leaf or stem) of ginseng to any processing.
As the optional processing, any one can be selected as long as it does not impair the effects of the present invention, and examples thereof include steaming, drying, heating, and extraction. These processes can be performed in an appropriate combination.
蒸煮処理とは対象となる原料植物(高麗人参の使用部位)を水蒸気共存下で加熱する処理である。蒸気加熱は蒸し器等の常圧で行ってもよいし、圧力釜等を利用して加圧した状態で行ってもよい。蒸煮する温度、時間は、高麗人参の使用部位や、後工程での処理方法等を考慮して適宜決定すればよいが、好適条件の一例を挙げると、常圧90℃〜100℃、8〜15時間である。 The steaming treatment is a treatment in which a target raw material plant (the site where ginseng is used) is heated in the presence of steam. The steam heating may be performed at a normal pressure of a steamer or the like, or may be performed in a pressurized state using a pressure cooker or the like. The temperature and time for steaming may be appropriately determined in consideration of the site of use of ginseng, the treatment method in the post-process, and the like, but examples of suitable conditions include normal pressure of 90 ° C to 100 ° C and 8 to 15 hours.
乾燥処理とは具体的には対象となる原料植物(高麗人参の使用部位)を、天日乾燥、加熱乾燥、フリーズドライ、減圧乾燥等の公知の乾燥方法で乾燥したものである。乾燥物は、使用性の観点から、通常、粉砕して粉末化され、乾燥粉砕物として使用される。粉砕方法は、特に限定はなく従来公知の粉砕器を使用すればよい。粉末の粒径は、その使用態様によって適宜決定される。 Specifically, the drying treatment is obtained by drying a target raw material plant (the site where ginseng is used) by a known drying method such as solar drying, heat drying, freeze drying, and vacuum drying. The dried product is usually pulverized and powdered from the viewpoint of usability, and used as a dried and pulverized product. The pulverizing method is not particularly limited, and a conventionally known pulverizer may be used. The particle size of the powder is appropriately determined depending on the mode of use.
加熱方法は公知の方法が採用でき、加熱条件は高麗人参の含有成分の作用を損なわない範囲で任意であり、対象となる原料植物(高麗人参の使用部位)、又はこれを必要に応じて他の処理(粉砕処理、細断処理、乾燥処理等)したものを任意の方法で加熱することである。 The heating method may be a known method, and the heating conditions are arbitrary as long as the effects of the components of ginseng are not impaired, and the target raw material plant (use site of ginseng) or, if necessary, other (Pulverization, shredding, drying, etc.) is heated by an arbitrary method.
抽出処理とは、対象となる原料植物(高麗人参の使用部位)、又はこれを必要に応じて粉砕処理、細断処理、乾燥処理、加熱処理したものを、圧搾又は溶媒抽出するなどして、有効成分の含有量を高めた形態のものにすることを総括した概念である。具体的には高麗人参の使用部位を抽出原料として得られる抽出液、該抽出液の希釈液若しくは濃縮液、又はこれらの粗精製物若しくは精製物のいずれもが含まれる。なお、抽出液を乾燥して得られる乾燥物も、抽出物に該当するものとする。 Extraction treatment is the target raw material plant (use site of ginseng), or, if necessary, crushing, shredding, drying, heat treatment, pressing or solvent extraction, etc. This is a general concept of making a form with an increased content of an active ingredient. Specifically, it includes an extract obtained by using a ginseng use site as an extraction raw material, a diluent or a concentrate of the extract, or any of these crude or purified products. Note that a dried product obtained by drying the extract is also considered to be an extract.
抽出処理に使用する抽出溶媒の具体例としては、水、メタノール、エタノール、プロパノール等の低級脂肪族アルコールが挙げられる。これらの抽出溶媒は単独又はこれら2種以上の混合物として使用することができ、2種以上の溶媒の混合液を抽出溶媒として使用する場合、その混合比は適宜調整することができる。 Specific examples of the extraction solvent used in the extraction treatment include water, lower aliphatic alcohols such as methanol, ethanol, and propanol. These extraction solvents can be used alone or as a mixture of two or more thereof. When a mixture of two or more solvents is used as the extraction solvent, the mixing ratio can be appropriately adjusted.
なお、抽出溶媒には、本発明の効果を損なわない範囲で添加剤を含んでいてもよい。例えば、pH調整剤、粘度調整剤などが挙げられる。 The extraction solvent may contain an additive within a range that does not impair the effects of the present invention. For example, a pH adjuster, a viscosity adjuster and the like can be mentioned.
原料植物から抽出物を抽出する方法は特に限定されず、常法に従って行なれる。例えば、原料植物を抽出溶媒に浸漬し、室温あるいは加熱して原料植物に含まれる可溶性成分を抽出する方法が挙げられる。また、抽出物に含まれる残渣を取り除くため、濾過や遠心分離を行ってもよい。また、得られた抽出液はそのまま利用してもよいが、常法に従って、熟成、希釈、濃縮、乾燥、精製等の処理を施してもよい。 The method for extracting the extract from the raw material plant is not particularly limited, and the extraction is performed according to a conventional method. For example, there is a method in which a raw material plant is immersed in an extraction solvent, and a soluble component contained in the raw material plant is extracted by heating at room temperature or under heating. Further, in order to remove the residue contained in the extract, filtration or centrifugation may be performed. The obtained extract may be used as it is, but may be subjected to treatment such as aging, dilution, concentration, drying, and purification according to a conventional method.
高麗人参の加工物は、それぞれ単独で使用してもよいし、他の成分と混合して使用してもよい。また、異なる加工処理を行ったもの(例えば、乾燥物と抽出物)を混合して使用してもよい。 The processed products of ginseng may be used alone or in combination with other components. Further, those that have been subjected to different processing (for example, a dried product and an extract) may be used as a mixture.
本発明において、好適な高麗人参の加工物として、蒸煮した根茎の乾燥物の粉砕物又は抽出物が挙げられる。蒸煮して乾燥させることにより根茎に含有される成分が凝縮される。特には、根茎(好ましくは6年根)を皮つきのまま蒸煮処理後、乾燥した乾燥物(いわゆる、紅参)を粉砕した粉砕物や抽出物(エキス)が好ましい。抽出物の抽出溶媒は、好適にはエタノール、又はエタノールと水の混合溶媒である。 In the present invention, a suitable processed product of ginseng includes a pulverized product or an extract of a dried steamed rhizome. By steaming and drying, the components contained in the rhizome are condensed. In particular, a pulverized product or extract (extract) obtained by pulverizing a dried and dried product (so-called red ginseng) after steaming the rhizome (preferably 6-year root) with the skin on it is preferable. The extraction solvent for the extract is preferably ethanol or a mixed solvent of ethanol and water.
本発明の経口組成物の好適な態様は、蒸煮した根茎の乾燥物の抽出物及びブドウ糖を含有し、顆粒状の経口組成物である。このような態様であれば、水やお湯に容易に溶解することができ、茶様飲料として常飲することができる。 A preferred embodiment of the oral composition of the present invention is a granular oral composition containing a dried extract of steamed rhizome and glucose. In such an embodiment, it can be easily dissolved in water or hot water and can be drunk as a tea-like beverage.
高麗人参の使用部位の加工物は、若齢者学習能力向上作用を有する。そのため、当該加工物を、本発明の経口組成物の有効成分として利用することができる。 The processed product of the ginseng use site has a function of improving the learning ability of young people. Therefore, the processed product can be used as an active ingredient of the oral composition of the present invention.
本明細書において、本発明の経口組成物の対象である「若齢者」とは10歳以上20歳以下の男女を意味する。より好適な対象は、13歳以上18歳以下の男女である。 As used herein, the term "young person", which is the subject of the oral composition of the present invention, means a man and a woman between 10 and 20 years old. More preferred subjects are men and women between the ages of 13 and 18 years.
また、「学習能力向上」とは、学習および/または記憶に関与する脳機能の向上を意味する。学習および/または記憶に関与する脳の作用としては例えば、注意、情報取得、情報処理、作動記憶、記憶検索、意思決定等が含まれるが、これらに限定されない。
本発明においては、学習能力向上は、ベントン視覚記銘検査、内田クレベリン検査、TK式田中AB知能検査のいずれかの検査(特にはベントン視覚記銘検査)で有意差が認められるか否かで評価するものとする。具体的には、実施例に記載する。
Further, “improvement in learning ability” means improvement in brain functions involved in learning and / or memory. Actions of the brain involved in learning and / or memory include, but are not limited to, attention, information acquisition, information processing, operational memory, memory retrieval, decision making, and the like.
In the present invention, the improvement of the learning ability depends on whether a significant difference is observed in any of the Benton visual memorization test, the Uchida-Kleberin test, and the TK Tanaka AB intelligence test (in particular, the Benton visual memorization test). Shall be evaluated. Specifically, this will be described in Examples.
本発明の経口組成物は、本発明の目的を損なわない範囲で上述の高麗人参由来の成分以外にも、脳機能の改善(例えば集中力向上、注意力向上等)に寄与する成分を配合していてもよい。 The oral composition of the present invention contains, in addition to the above-mentioned ginseng-derived components, components that contribute to improvement of brain function (for example, improvement of concentration and attention) as long as the object of the present invention is not impaired. May be.
本発明の経口組成物の形態は、特に制限されず使用する用途により適宜選択することができる。具体的には粉末状、顆粒状、カプセル状、タブレット状、グミ状、ガム状、キャンディー状、丸剤、錠剤状、棒状、板状、液状、クリーム状、軟膏状、シート状等の剤型・形態をとることができる。この中でも、錠剤状、粉末状、液状、顆粒状又はカプセル状であることが好ましい。
なお、製剤化する場合、保存や取扱いを容易にするために、薬学的に許容され得る担体やその他任意の助剤を添加することができる。
The form of the oral composition of the present invention is not particularly limited and can be appropriately selected depending on the intended use. Specifically, dosage forms such as powder, granule, capsule, tablet, gummy, gum, candy, pill, tablet, stick, plate, liquid, cream, ointment, sheet, etc.・ It can take the form. Among these, a tablet, powder, liquid, granule or capsule is preferable.
In the case of formulation, a pharmaceutically acceptable carrier or any other auxiliary agent can be added to facilitate storage and handling.
本発明の経口組成物の摂取量は、高麗人参の使用部位、加工方法、経口組成物の形態や、対象者の年齢、性別などの個別差にもよって適宜決定すればよい。摂取量の一例は、含有するジンセノサイド(Rg1+Rb1+Rg3)量換算で、1日当たり、通常、2〜100mg程度である。 The intake of the oral composition of the present invention may be appropriately determined depending on the site of use of ginseng, the processing method, the form of the oral composition, and individual differences such as the age and gender of the subject. One example of the intake amount is usually about 2 to 100 mg per day in terms of the amount of ginsenoside (Rg1 + Rb1 + Rg3) contained.
本発明の経口組成物は、安全な植物由来であるため、安全で嗜好的にも優れる。そのため、日常的に経口摂取しやいように、各種の食品、飲料と混ぜて機能性食品とすることで、長期的に摂取することも容易である。ここでいう「機能性食品」とは、一般食品に加えて、健康食品、栄養補助食品、栄養機能食品、栄養保健食品等、健康の維持の目的で摂取する食品および/又は飲料を意味している。なお、機能性食品として製品化する場合には、食品に用いられる様々な添加剤、具体的には、着色料、保存料、増粘安定剤、酸化防止剤、漂白剤、防菌防黴剤、酸味料、調味料、乳化剤、強化剤、製造用剤、香料等を添加していてもよい。 Since the oral composition of the present invention is derived from a safe plant, it is safe and excellent in taste. Therefore, it is easy to ingest it for a long time by mixing it with various foods and beverages to make a functional food so that it is easily taken orally on a daily basis. The term "functional food" as used herein means, in addition to general foods, foods and / or beverages taken for the purpose of maintaining health, such as health foods, dietary supplements, nutritional functional foods, nutritional health foods, and the like. I have. When commercialized as functional foods, various additives used in foods, specifically, colorants, preservatives, thickeners, antioxidants, bleaching agents, fungicides and fungicides , Acidulants, seasonings, emulsifiers, strengthening agents, manufacturing agents, flavors and the like may be added.
本発明の機能性食品の対象となる、食品、飲料は特に限定されるものではない。例えば、食品として、例えば、菓子,パン等の穀物の加工品が挙げられる。また、飲料としては、各種の茶類、清涼飲料水、酒類、栄養ドリンクなどが挙げられる。本発明の経口組成物は、このような食品、飲料に添加することにより、簡易に経口摂取することができる。 Foods and beverages that are targets of the functional food of the present invention are not particularly limited. For example, as foods, processed products of cereals such as confectionery and bread are exemplified. Examples of the beverage include various teas, soft drinks, alcoholic beverages, and energy drinks. The oral composition of the present invention can be easily taken orally by adding it to such foods and beverages.
本発明の経口組成物は、ヒト以外の動物に対して適用することもできる。そのため、動物用の経口組成物として使用してもよく、また、ペットフード等の動物用機能性食品へ添加することもできる。 The oral composition of the present invention can also be applied to animals other than humans. Therefore, it may be used as an oral composition for animals, or may be added to functional foods for animals such as pet food.
以下に実施例を挙げて本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 Hereinafter, the present invention will be described more specifically with reference to Examples, but the present invention is not limited thereto.
<1.試料の調製>
原料として高麗人参の根茎(6年根)を洗浄後、常圧、水蒸気共存下、95℃、10時間の条件で蒸煮処理を行った。次いで、常温で30時間、乾燥処理(通風乾燥)を行った。乾燥処理後の根茎を所定のタンクに入れ、加熱したエタノールで抽出し、ろ過で不純物を取り除くことにより、抽出物(エキス)を得た。この操作を繰り返し、得られたエキスを混合して目的とする高麗人参エキス(「ONG−90HN」と命名)を得た。この高麗人参エキスが17重量%となるように、基剤(ブドウ糖、乳糖、ビタミンCの混合物)に配合し、実施例の試料(顆粒状)を得た。
<1. Preparation of sample>
The ginseng rhizome (6-year root) was washed as a raw material, and then steamed at 95 ° C. for 10 hours in the presence of steam at normal pressure. Next, a drying treatment (ventilation drying) was performed at room temperature for 30 hours. The rhizome after the drying treatment was put into a predetermined tank, extracted with heated ethanol, and impurities were removed by filtration to obtain an extract (extract). This operation was repeated, and the resulting extracts were mixed to obtain the desired ginseng extract (named “ONG-90HN”). This ginseng extract was blended with a base (a mixture of glucose, lactose, and vitamin C) so as to be 17% by weight to obtain a sample (granular) of the example.
プラセボ品として、を含まない基剤からなる試料(顆粒状)を調製した。 As a placebo product, a sample (granular) consisting of a base not containing was prepared.
<2.評価>
実施例の試料の効果を検証するために、二重盲検ランダム化並行群間比較試験を行った。
健常な小児男女(13歳以上18歳以下)40名を対象に、比較例の試料(プラセボ茶)を摂取する20名はプラセボ群として、実施例の試料を摂取する20名は試験物群として割り当て、摂取前、摂取28日(4週間)後でのベントン視覚記銘検査、内田クレペリン検査(計算課題)及びTK式田中AB式知能検査を用いて評価した。
詳細以下の通りである。
<2. Evaluation>
In order to verify the effects of the samples of the examples, a double-blind, randomized, parallel group comparison test was performed.
For 40 healthy males and females (13 to 18 years old), 20 subjects taking the sample of the comparative example (placebo tea) were taken as a placebo group, and 20 people taking the sample of the example were taken as a test group. Evaluation was made using the Benton visual memorization test, the Uchida-Kraepelin test (calculation task), and the TK Tanaka AB-type intelligence test before assignment, before ingestion, and 28 days (4 weeks) after ingestion.
Details are as follows.
割付けには、試験に関係ない責任者が年齢、性別で無作為抽出法を用いて、プラセボ群に20名、試験物群に20名に割付けた。
プラセボ群20名(平均年齢15.6歳:男児4名、女児16名)
試験物群20名(平均年齢15.9歳:男児4名、女児16名)
Assignments were made by a person unrelated to the study to 20 persons in the placebo group and 20 persons in the test group using a random sampling method based on age and gender.
Placebo group 20 (average age 15.6 years: 4 boys, 16 girls)
Test article group 20 (average age 15.9 years: 4 boys, 16 girls)
試験物群では上記実施例の試料を1日1包(3g)を、水(約100mL)に溶解し、経口摂取させた(試験物群)。また、プラセボ群では上記比較例の試料を1日1包(3g)を、水(約100mL)に溶解し、経口摂取させたプラセボ群)。試験物群、プラセボ群共に摂取期間は28日間(4週間)とした。 In the test group, one sample (3 g) of the sample of the above example was dissolved in water (about 100 mL) per day and orally ingested (test group). In the placebo group, one sample (3 g) of the sample of the comparative example was dissolved in water (about 100 mL) a day and taken orally (the placebo group). The intake period was set to 28 days (4 weeks) for both the test substance group and the placebo group.
<試験結果>
(解析対象者)
試験物群、プラセボ群40名のうち、途中離脱により試験物群から3名除外したため、37名を解析対象とした。なお、摂取日数を用いて算出した摂取率は、プラセボ群91.3%(n=20)、試験物群94.7%(n=17)であった。
<Test results>
(Analyzer)
Of the 40 test article groups and the placebo group, 3 were excluded from the test article group due to withdrawal on the way, and therefore 37 were analyzed. The intake rate calculated using the number of intake days was 91.3% (n = 20) in the placebo group and 94.7% (n = 17) in the test substance group.
(評価1)ベントン視覚記銘検査
ベントン視覚記銘検査は、視覚による記憶検査である。被験者には数種類の無意味図形が描かれたカード(図1の例参照)を10秒見せて覚えてもらい、その後カードを伏せて、白い紙に図形の形・位置・大きさなどを出来るだけ正確に描くよう指示した。カードは10枚あり、ほぼ誤りなく描かれた場合に1点を付与し、合計10点満点で成績をつけた。同レベルに設定した検査が3セット(それぞれA、B、C)準備されており、摂取前にA、摂取後にBを実施することで、出来るだけ試験ごとによる練習の効果を排除するようにした。
表1にベントン視覚記銘検査における点数を各群の摂取前後で比較した結果を示した。プラセボ群では摂取前後の比較に有意な差は認められなかった。一方、試験物群においては摂取後の点数が摂取前よりも有意に高い傾向が認められた(p<0.1)。
また、表2にプラセボ群と試験物群で比較した結果を示した。プラセボ群と試験物群の比較では、有意な差は認められなかった(図2)。
(Evaluation 1) Benton visual memorization inspection Benton visual memorization inspection is a visual memory inspection. The subject showed the card with several meaningless figures drawn (see the example in Fig. 1) for 10 seconds, and then laid down the card, and then turned the card down on white paper as much as possible in shape, position and size. Instructed to draw accurately. There were 10 cards, and if they were drawn with almost no errors, one point was awarded, and the score was given out of a total of ten points. Three sets of tests (A, B, and C, respectively) set at the same level are prepared, and by performing A before intake and B after intake, the effect of practice by each test is eliminated as much as possible. .
Table 1 shows the results of comparing the scores in the Benton visual memorization test before and after ingestion of each group. No significant difference was observed in the placebo group before and after ingestion. On the other hand, in the test article group, scores after ingestion tended to be significantly higher than before ingestion (p <0.1).
Table 2 shows the results of comparison between the placebo group and the test article group. No significant difference was observed between the placebo group and the test article group (FIG. 2).
ベントン視覚記銘検査において、プラセボ群では摂取前後の比較に有意な差は認められなかった。一方、試験物群では、摂取後の点数が摂取前よりも有意に高い傾向が認められた。また、プラセボ群では摂取後に平均点数が0.40の下降を示し、試験物群では摂取後に0.71の上昇が示されたことから、実施例1の試料を摂取することで記憶力を向上する効果がある可能性が示唆された。 In the Benton visual memorization test, no significant difference was observed in the placebo group before and after ingestion. On the other hand, in the test article group, scores after ingestion tended to be significantly higher than before ingestion. In addition, the placebo group showed a decrease in average score of 0.40 after ingestion, and the test article group showed an increase of 0.71 after ingestion. Therefore, ingestion of the sample of Example 1 improves memory ability. It was suggested that it might be effective.
(評価2)内田クレペリン検査用紙を使用した計算課題
内田クレペリン検査の用紙(図3の例参照)を使用して、簡単な一桁の足し算を10分間行い、その正答数を摂取前、摂取後で比較した。
表3に内田クレペリン検査用紙を使用した計算課題における正答数を各群の摂取前後で比較した結果を示した。プラセボ群、試験物群ともに摂取後の点数は摂取前よりも有意に高い点数となった(p<0.01)。
表4に正答数をプラセボ群と試験物群で比較した結果を示した。プラセボ群と試験物群の比較においては、摂取前、摂取後ともに試験物群が有意に高い傾向が認められた(p<0.1、図4)。
(Evaluation 2) Calculation task using Uchida-Kraepelin test paper Using a Uchida-Kraepelin test paper (see the example in Fig. 3), perform a simple single-digit addition for 10 minutes, and calculate the number of correct answers before and after ingestion Was compared.
Table 3 shows the results of comparing the number of correct answers in the calculation task using the Uchida-Kraepelin test paper before and after ingestion of each group. Both the placebo group and the test article group scored significantly higher after ingestion than before ingestion (p <0.01).
Table 4 shows the results of comparing the number of correct answers between the placebo group and the test article group. In the comparison between the placebo group and the test article group, the test article group tended to be significantly higher both before and after ingestion (p <0.1, FIG. 4).
内田クレペリン検査用紙を使用した計算課題において、プラセボ群、試験物群ともに摂取後の点数は摂取前よりも有意に高い値となった。プラセボ群では摂取後に平均点数が66.05の上昇を示し、試験物群では摂取後に80.36の上昇が示された。両群ともに摂取後の点数が上昇したのは、問題に対する慣れが生じたのではないかと考えられる。しかし、数値的にみると点数の上昇はプラセボ群に比べて試験物群の方が大きかったことから、試験物の摂取が計算能力にプラスの効果があるのではないかと考えられた。 In the calculation task using the Uchida-Kraepelin test sheet, the scores after ingestion of both the placebo group and the test article group were significantly higher than before ingestion. In the placebo group, the average score increased by 66.05 after ingestion, and in the test group, the average score increased by 80.36 after ingestion. The rise in scores after ingestion in both groups may be a sign of acclimatization to the problem. However, numerically, the increase in score was greater in the test group than in the placebo group, suggesting that ingestion of the test sample might have a positive effect on computational ability.
(評価3)TK式田中AB式知能検査
言語式(A式)と非言語式(B式)を併用し、総合的に知能が測定できる知能検査である。この検査は6つの問題領域(図5参照)からなっており、易しい問題から難しい問題まで、幅広い問題で構成されている。また問題の配列が螺旋式となっているため、測定誤差が少ない検査となっている。この検査を25分間行った。
表5にTK式田中AB式知能検査における知能偏差値を各群の摂取前後で比較した結果を示した。プラセボ群、試験物群ともに摂取後の知能偏差値は摂取前よりも有意に高い点数が認められた(p<0.01、図6)。
(Evaluation 3) TK-type Tanaka AB-type intelligence test This is an intelligence test that uses a linguistic expression (expression A) and a non-linguistic expression (expression B) in combination and can measure intelligence comprehensively. This test consists of six problem areas (see FIG. 5), and consists of a wide range of problems, from easy to difficult. In addition, since the array in question is of a spiral type, the inspection has a small measurement error. This inspection was performed for 25 minutes.
Table 5 shows the results of comparison of intelligence deviation values in the TK Tanaka AB intelligence test before and after ingestion of each group. In both the placebo group and the test substance group, scores of the intelligence deviation after ingestion were significantly higher than before ingestion (p <0.01, FIG. 6).
表6に問題領域別の粗点を摂取前後で比較した結果を示した。プラセボ群では、問題A,B,C,D,Eにおいて摂取後は摂取前よりも有意に高い点数となった(p<0.01)が、問題F(数学的能力)においては摂取前後に有意な差は認められなかった。試験物群では、問題A,B,C,D,Eにおいて摂取後は摂取前よりも有意に高い点数となった(p<0.01)。問題F(数学的能力)においても摂取後は摂取前よりも有意に高い点数となった(p<0.05)。 Table 6 shows the results of comparing the rough score of each problem area before and after ingestion. In the placebo group, the scores after ingestion in questions A, B, C, D, and E were significantly higher than before ingestion (p <0.01), but in question F (mathematical ability) before and after ingestion No significant difference was found. In the test article group, the scores after the ingestion in the questions A, B, C, D, and E were significantly higher than before the ingestion (p <0.01). Question F (mathematical ability) also scored significantly higher after ingestion than before ingestion (p <0.05).
表7に知能偏差値をプラセボ群と試験物群で比較した結果を示した。プラセボ群と試験物群の知能偏差値の比較では、有意な差は認められなかった。
表8に問題領域別の粗点をプラセボ群と試験物群で比較した結果を示した。摂取前の問題C(言語的関係理解)において試験物群が有意に低い点数となった(p<0.05)。摂取後のプラセボ群と試験物群では、全ての問題において有意な差は認められなかった。
Table 7 shows the results of comparing the intelligence deviation values between the placebo group and the test article group. No significant difference was observed in the comparison of the intelligence deviation between the placebo group and the test article group.
Table 8 shows the results of the comparison of the rough score for each problem area between the placebo group and the test article group. The test article group scored significantly lower in Question C (linguistic relationship understanding) before ingestion (p <0.05). There were no significant differences in all issues between the placebo group and the test group after ingestion.
TK式田中AB式知能検査において、プラセボ群、試験物群ともに摂取後の知能偏差値は摂取前よりも有意に高い値となった。プラセボ群では摂取後に知能偏差値が9.05の上昇を示し、試験物群では摂取後に11.18の上昇が見られた。両群ともに摂取後の点数が上昇したのは、問題に対する慣れが生じたのではないかと考えられる。しかし、数値的にみると知能偏差値の上昇はプラセボ群に比べて試験物群の方が大きかったことから、試験物の摂取が知能検査問題にプラスの効果があるのではないかと考えられた。問題領域別の粗点を摂取前後で比較すると、問題A,B,C,D,Eにおいてはプラセボ群、試験物群ともに摂取後は摂取前よりも有意に高い点数となった。問題F(数学的能力)に関して、プラセボ群では摂取前後に有意な差はみられなかったが、試験物群では摂取後は摂取前よりも有意に高い点数となった。このことから、試験物の摂取が特に数学的能力に対してプラスの効果があるのではないかと考えられた。また、問題領域別にプラセボ群と試験物群で比較すると、問題C(言語的関係理解)において摂取前はプラセボ群が有意に高い点数となったが、摂取後には有意な差は認められなかった。 In the TK Tanaka AB-type intelligence test, the intellectual deviation after ingestion of both the placebo group and the test article group was significantly higher than before ingestion. The placebo group showed an increase in intelligence deviation of 9.05 after ingestion, and the test group showed an increase of 11.18 after ingestion. The rise in scores after ingestion in both groups may be a sign of acclimatization to the problem. However, numerically, the increase in intelligence deviation was greater in the test group than in the placebo group, suggesting that ingestion of the test sample might have a positive effect on the intelligence test problem. . Comparing the rough scores for each of the problem areas before and after ingestion, the scores for the placebo group and the test article group in the questions A, B, C, D, and E were significantly higher after ingestion than before ingestion. Regarding question F (mathematical ability), no significant difference was observed before and after ingestion in the placebo group, but the test article group scored significantly higher after ingestion than before ingestion. This suggested that ingestion of the test article had a positive effect, especially on mathematical performance. When the placebo group and the test article group were compared according to the problem area, the placebo group scored significantly higher before ingestion in Problem C (understanding linguistic relationship), but no significant difference was observed after ingestion. .
以上の通り、ベントン視覚記銘検査の試験物群において、摂取後にスコアの有意な上昇傾向が確認された。また、内田クレペリン検査及びTK式田中AB式知能検査の試験物群においても、摂取後にスコアの有意な上昇が確認された。
以上の結果から、若齢者の高麗人参エキスの摂取が学習能力の向上効果を有すると考えられる。
As described above, in the test group of the Benton visual memorization test, a significant increase in the score after ingestion was confirmed. In the test group of the Uchida-Kraepelin test and the TK-type Tanaka AB-type intelligence test, a significant increase in the score after ingestion was also confirmed.
From the above results, it is considered that the ingestion of ginseng extract by young people has the effect of improving learning ability.
本発明の経口組成物を摂取することにより、若齢者の学習能力向上するため、産業的に有望である。 Ingestion of the oral composition of the present invention improves the learning ability of young people, and is therefore industrially promising.
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018115554A JP2019218284A (en) | 2018-06-18 | 2018-06-18 | Oral composition for improving juvenile learning ability, and method for improving juvenile learning ability |
JP2019230367A JP7383281B2 (en) | 2018-06-18 | 2019-12-20 | Oral composition and functional food for improving learning ability of young people |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018115554A JP2019218284A (en) | 2018-06-18 | 2018-06-18 | Oral composition for improving juvenile learning ability, and method for improving juvenile learning ability |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019230367A Division JP7383281B2 (en) | 2018-06-18 | 2019-12-20 | Oral composition and functional food for improving learning ability of young people |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019218284A true JP2019218284A (en) | 2019-12-26 |
Family
ID=69095871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018115554A Withdrawn JP2019218284A (en) | 2018-06-18 | 2018-06-18 | Oral composition for improving juvenile learning ability, and method for improving juvenile learning ability |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2019218284A (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001056585A1 (en) * | 2000-01-31 | 2001-08-09 | Digital Biotech Co., Ltd | Cognitive enhancer comprising ginseng extract |
CN101327010A (en) * | 2008-07-07 | 2008-12-24 | 吉林省宏久生物科技股份有限公司 | Method for preparing amber ginseng |
CN101385734A (en) * | 2008-10-30 | 2009-03-18 | 珍奥集团股份有限公司 | Use of ginsenoside in preparing food and medicine for preventing age associated memory impairment and Alzheimer's disease associated dysmnesia |
KR20110005144A (en) * | 2009-07-09 | 2011-01-17 | 대한민국(농촌진흥청장) | Pharmaceutical composition and health-food composition containing ginseng extracts having neuroprotective effects |
KR101304707B1 (en) * | 2011-01-28 | 2013-09-06 | 경희대학교 산학협력단 | Improvemnet composition including ginseng for cognitive function |
KR20130115951A (en) * | 2012-04-13 | 2013-10-22 | 경희대학교 산학협력단 | Composition comprising ginsenoside re as an active ingredient for treatment of depression, anxiety or learnig and memory impairments |
CN103800410A (en) * | 2014-01-15 | 2014-05-21 | 吉林大学 | Cultivated ginseng ethanol extract with function of improving studying memory |
JP2015535241A (en) * | 2012-10-30 | 2015-12-10 | 協和発酵バイオ株式会社 | Preventing or improving brain function |
JP2016515611A (en) * | 2013-04-02 | 2016-05-30 | 株式会社アモーレパシフィックAmorepacific Corporation | Brain-activating composition containing ginseng fruit extract |
JP2016128427A (en) * | 2015-01-09 | 2016-07-14 | 株式会社アモーレパシフィックAmorepacific Corporation | Composition comprising panax ginseng extract having enhanced ginsenoside content as active ingredient |
JP2017178914A (en) * | 2016-03-31 | 2017-10-05 | 株式会社ニュートリション・アクト | Composition for improving and enhancing brain function |
WO2018079695A1 (en) * | 2016-10-28 | 2018-05-03 | ゼリア新薬工業株式会社 | Inhibitor for cognitive function decline |
-
2018
- 2018-06-18 JP JP2018115554A patent/JP2019218284A/en not_active Withdrawn
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001056585A1 (en) * | 2000-01-31 | 2001-08-09 | Digital Biotech Co., Ltd | Cognitive enhancer comprising ginseng extract |
CN101327010A (en) * | 2008-07-07 | 2008-12-24 | 吉林省宏久生物科技股份有限公司 | Method for preparing amber ginseng |
CN101385734A (en) * | 2008-10-30 | 2009-03-18 | 珍奥集团股份有限公司 | Use of ginsenoside in preparing food and medicine for preventing age associated memory impairment and Alzheimer's disease associated dysmnesia |
KR20110005144A (en) * | 2009-07-09 | 2011-01-17 | 대한민국(농촌진흥청장) | Pharmaceutical composition and health-food composition containing ginseng extracts having neuroprotective effects |
KR101304707B1 (en) * | 2011-01-28 | 2013-09-06 | 경희대학교 산학협력단 | Improvemnet composition including ginseng for cognitive function |
KR20130115951A (en) * | 2012-04-13 | 2013-10-22 | 경희대학교 산학협력단 | Composition comprising ginsenoside re as an active ingredient for treatment of depression, anxiety or learnig and memory impairments |
JP2015535241A (en) * | 2012-10-30 | 2015-12-10 | 協和発酵バイオ株式会社 | Preventing or improving brain function |
JP2016515611A (en) * | 2013-04-02 | 2016-05-30 | 株式会社アモーレパシフィックAmorepacific Corporation | Brain-activating composition containing ginseng fruit extract |
CN103800410A (en) * | 2014-01-15 | 2014-05-21 | 吉林大学 | Cultivated ginseng ethanol extract with function of improving studying memory |
JP2016128427A (en) * | 2015-01-09 | 2016-07-14 | 株式会社アモーレパシフィックAmorepacific Corporation | Composition comprising panax ginseng extract having enhanced ginsenoside content as active ingredient |
JP2017178914A (en) * | 2016-03-31 | 2017-10-05 | 株式会社ニュートリション・アクト | Composition for improving and enhancing brain function |
WO2018079695A1 (en) * | 2016-10-28 | 2018-05-03 | ゼリア新薬工業株式会社 | Inhibitor for cognitive function decline |
Non-Patent Citations (10)
Title |
---|
BAO H.Y. ET AL.: "Memory Enhancing and Neuroprotective Effects of Selected Ginsenosides", ARCH PHARM RES, vol. 28, no. 3, JPN6019031452, 2005, pages 335 - 342, XP053007129, ISSN: 0004136871, DOI: 10.1007/BF02977802 * |
KENNEDY, D.O. ET AL.: "Dose Dependent Changes in Congnitive Performance and Mood following Acute Administration of Ginseng", NUTRITIONAL NEUROSCIENCE, vol. 4, no. 4, JPN6019040370, 31 December 2001 (2001-12-31), pages 295 - 310, ISSN: 0004326640 * |
NISHIJO H. ET AL.: "RED GINSENG AMELIORATES LEARNING DEFICITS IN YOUNG RATS WITH HIPPOCAMPAL LESIONS AND AGED RATS", JAPANESE JOURNAL OF PHYSIOLOGY, vol. 53, JPN6019031448, 2003, pages 90, ISSN: 0004200002 * |
PERSSON J. ET AL.: "The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy volunteers", PSYCHOPHARMACOLOGY, vol. 172, JPN6019031453, 25 November 2003 (2003-11-25), pages 430 - 434, ISSN: 0004200004 * |
PETKOV V. D. ET AL.: "Memory Effects of Standardized Extracts of Panax ginseng (G115), Ginkgo biloba (GK501) and their com", PLANTA MEDICA, vol. 59, JPN6019031455, April 1993 (1993-04-01), pages 106 - 114, XP001029819, ISSN: 0004136872 * |
WANG Y. ET AL.: "Structural and enhanced memory activity studies of extracts from Panax ginseng root", FOOD CHEMISTRY, vol. 119, JPN6019031454, 2010, pages 969 - 973, XP026754869, ISSN: 0004136870, DOI: 10.1016/j.foodchem.2009.07.061 * |
包 天桐 ら: "紅参,ビタミン類およびその配合剤の効果(第III報)−ストレス負荷雄性マウスの学習行動,性行動に対す", 薬理と治療, vol. 12, no. 4, JPN6019031450, April 1984 (1984-04-01), pages 30 - 36, ISSN: 0004326637 * |
堀 宏治ら: "記憶の神経心理学的評価法", 老年精神医学雑誌, vol. 第23巻、第2号, JPN6019040372, February 2012 (2012-02-01), pages 229 - 233, ISSN: 0004326641 * |
宇野 洋太: "解法者におけるリスクアセスメントのための知的発達評価技法の研究および開発", 2013年度若手研究助成最終報告書, JPN6019040374, 2013, pages 1 - 13, ISSN: 0004326642 * |
食品と開発, vol. 36, no. 10, JPN6020030153, 2001, pages 61 - 63, ISSN: 0004326643 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101498780B1 (en) | Composition for preventing or treating hangover | |
EP1467627A1 (en) | Method for processing ginseng and the uses of extract of processed ginseng | |
KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
Yampolsky et al. | Dates (Phoenix dactylifera) | |
KR100549089B1 (en) | A Health Care Composition for treating or preventing intestinal disease and constipation | |
JP2010275288A (en) | Functional composition for preventing and improving hangover, food and food additive containing the same | |
KR101061575B1 (en) | Drinks containing red ginseng and plant extracts | |
JP6844857B2 (en) | A skin moisturizing composition containing acacia bark-derived products | |
JP7383281B2 (en) | Oral composition and functional food for improving learning ability of young people | |
JP2018506524A (en) | Composition for prevention, amelioration or treatment of burnout syndrome | |
JP2019218284A (en) | Oral composition for improving juvenile learning ability, and method for improving juvenile learning ability | |
KR100506824B1 (en) | Crude Drug Compositions for treating or preventing intestinal disease and constipation | |
KR20190102493A (en) | A pill for functional food comprising Protaetia brevitarsis seulensis and manufacturing method therof | |
JP6757995B2 (en) | Oral composition | |
JP2022124984A (en) | Lipase activity inhibitor and use thereof | |
JP6141071B2 (en) | Skin moisture increasing agent | |
Tijani et al. | Phytochemical and Nutraceutical Potentials of Beach Bean (Canavalia rosea SW.) DC Grown in Anyigba, Kogi State, Nigeria | |
JP2004323439A (en) | Composition for ameliorating blood viscosity | |
JP2012131760A (en) | Fatty acid absorption inhibitor | |
KR100872310B1 (en) | Functional composition for the cotinene metabolism improvement which is caused by with smoking and hangover removal, foods and food additive containing the same | |
KR102696923B1 (en) | Concentrate composition comprising acanthopanax senticosus and method for preparing thereof | |
Satish et al. | A STUDY TO EVALUATE POTENTIAL ANTIOBESITY ACTIVITY OF ETHANOLIC PULP EXTRACT OF CUCUMIS MELO LINN USING CAFETERIA DIET MODEL IN RATS | |
KR20150120741A (en) | Composition for preventing or improving atopic dermatitis comprising mixture of persimmon peel, persimmon flesh, persimmon leaf and Diospyros lotus leaf as effective component | |
JP7368340B2 (en) | Composition for inhibiting phosphodiesterase 5 | |
US20240207339A1 (en) | Composition comprising a phytocomplex from pomegranate and its uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190710 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20190710 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190730 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191220 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200427 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200427 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200512 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200610 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200616 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20200821 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20200901 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20201222 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210413 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210714 |
|
C27C | Written answer of applicant after an oral proceeding |
Free format text: JAPANESE INTERMEDIATE CODE: C2721 Effective date: 20210907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210921 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20211116 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20220113 |